Lonza (Switzerland) has submitted a non-binding proposal that would see it acquire all of the Restricted Voting Shares of US-based Patheon Inc.
Lonza (Switzerland) has submitted a non-binding proposal that would see it acquire all of the Restricted Voting Shares of US-based Patheon Inc. However, a statement released via PR Newswire by JLL, a private equity investment firm based in New York (US) and the single largest shareholder of Patheon, has suggested that the transaction will face opposition.
"JLL is not interested in selling its position in Patheon at this time. JLL will not enter into negotiations regarding the Lonza proposal and Patheon shareholders should be aware that a transaction with Lonza cannot occur without JLL's support," said the JLL statement.
JLL made an offer to acquire the same shares as Lonza in March 2009 for $2 per share, but the bid was described by the Patheon Special Committee as "substantially undervalued, opportunistic and coercive". Lonza, however, has offered to pay $3.55 per share and, unsurprisingly, Patheon seems much happier with this proposal.
"Based on all the information available to it, the Special Committee's view has been that Patheon continuing as an independent company is a more attractive alternative to the JLL offer," Paul Currie, Chairman of the Special Committee of Independent Directors of Patheon, explained in a joint statement issued by Lonza and Patheon. "The Special Committee also believes that the Lonza proposal would provide an excellent opportunity to secure the successful future development of Patheon, and that it is in the best interest of all Patheon shareholders to explore the Lonza proposal further."
Lonza also seems enthusiastic. "Our interest in Patheon is consistent with Lonza's strategy of expanding our offering across the pharmaceutical manufacturing value chain," Lonza's CEO, Stefan Borgas, said in the joint statement.
But whether the transaction will take place remains to be seen. Lonza has signed a confidentiality and standstill agreement, and Patheon has agreed not to negotiate an acquisition transaction with any other party until 30 September 2009. However, JLL is adamant that it "holds Restricted Voting Shares that represent approximately 57% of the shares outstanding" and that "the Lonza proposal is conditioned on, among other things, acceptance of the Lonza proposal by the holders of at least 67% of the outstanding Patheon Restricted Voting Shares".
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
2 Commerce Drive
Cranbury, NJ 08512